Search

Home > New FDA Approvals > 013 – FDA Approves Axicabtagene Ciloleucel (Yescarta) for Non-Hodgkin Lymphoma; US FDA panel backs approval of Novo Nordisk diabetes drug semaglutide; FDA Accepts Myriad BRAC Analysis CDx Supplementary PMA as a Companion Diagnostic for Lynparza
Podcast: New FDA Approvals
Episode:

013 – FDA Approves Axicabtagene Ciloleucel (Yescarta) for Non-Hodgkin Lymphoma; US FDA panel backs approval of Novo Nordisk diabetes drug semaglutide; FDA Accepts Myriad BRAC Analysis CDx Supplementary PMA as a Companion Diagnostic for Lynparza
Category: Science & Medicine
Duration: 0
Publish Date: 2017-10-19 06:00:00
Description:

1:31 FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma

The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with relapsed or non Hodgkins lymphoma.

http://www.gilead.com/news/press-releases/2017/10/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-bcell-lymphoma-after-two-or-more-lines-of-systemic-therapy

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma

4:24 US FDA panel backs approval of Novo Nordisk diabetes drug semaglutide, saying it is effective, reasonably safe and should be approved.

6:05 FDA Accepts Myriad BRAC Analysis CDx Supplementary PMA as a Companion Diagnostic for Lynparza® (olaparib) in Metastatic Breast Cancer.

https://myriad.com/investors/press-release-detail/?newsItemId=1044316

Check out our medical writing services at nascentmc.com or email info@nascentmc.com
Total Play: 0